Ligand submits Onzar MAA

LGND submitted an MAA for European marketing approval of its Onzar denileukin diftitox ( DAB389IL2) to treat cutaneous T-cell lymphoma (CTCL). The submission triggers a $1 million milestone to LGND fr...